Pluses and minuses of the weight-loss drug bonanza
Obesity treatments made by Novo Nordisk (https://www.breakingviews.com/columns/breaking-view/novos-timely-board-medicine-leaves-ongoing-malady-2025-10-21/) and Eli Lilly have spawned (https://www.reuters.com/commentary/breakingviews/obesity-kings-buffet-is-slimmer-than-it-looks-2025-10-02/) a healthcare revolution (https://www.reuters.com/commentary/breakingviews/pfizers-obesity-win-is-new-formula-pharma-ma-2025-11-10/) , with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins – and theirContinue Reading












